Trichomonas vaginalis
Revu par Dr Hayley Willacy, FRCGP Dernière mise à jour par Dr Toni Hazell, FRCGPDernière mise à jour 30 mars 2026
Respecte les directives éditoriales
- TéléchargerTélécharger
- Partager
- Language
- Discussion
- Ask Patient
- Version audio
- Ajouter aux sources préférées sur Google
Professionnels de la santé
Les articles de référence professionnelle sont conçus pour être utilisés par les professionnels de la santé. Ils sont rédigés par des médecins britanniques et basés sur des preuves de recherche, des directives britanniques et européennes. Vous pouvez trouver le Trichomonase article plus utile, ou l'un de nos autres articles de santé.
What is trichomonas vaginalis?
Trichomonas vaginalis (TV) is a common sexually transmitted infection (STI) that can cause vaginitis, cervicitis and urethritis.
What causes trichomonas vaginalis?
Trichomonas vaginalis is a flagellated protozoan.
Trichomonas vaginalis is a member of the Parabasalia, a group of single-celled eukaryotes within the clade Excavata, which also includes parasites of genera such as Giardia et Trypanosoma.1
In women the organism is found in the vagina, urethra and paraurethral glands.
Urethral infection is present in 90% of infected women.2
In men, infection is usually of the urethra.
In adults, transmission is almost exclusively through sexual intercourse.
Épidémiologie 34
Trichomonas vaginalis is the most common curable STI worldwide - in 2020, there were around 156 million cases of T. vaginalis worldwide, accounting for almost half of the global STI incidence that year.
It is less common in the UK, with chlamydia being the most common STI.
Despite having the highest prevalence of any STI globally, there is a dearth of data describing Trichomonas vaginalis incidence and prevalence in the general population .
Trichomonas vaginalis is still probably underdiagnosed (as asymptomatic people do not seek a diagnosis) and therefore undertreated.
Trichomonas vaginalis symptoms
Les femmes5
Les symptômes de Trichomonas vaginalis can be confused with bacterial vaginosis (BV).
Up to 50% of women with TV are asymptomatic - of those who have symptoms, around 70% of women have a vaginal discharge.
Although this is usually a frothy yellowish discharge, it can vary from being thin and scanty to profuse and thick.
Other common symptoms include vulval itching, dysuria or offensive odour.
Lower abdominal discomfort can occur in some women.
There may be signs of local inflammation with vulvitis and vaginitis.
Cervicitis may be present which leads to the cervix having the appearance of the surface of a strawberry; sometimes referred to a 'strawberry cervix'.
Hommes6
Men are usually asymptomatic.
Trichomonas vaginalis is increasingly being recognised as a cause of non-gonococcal urethritis.
The most common symptoms are dysuria and presence of a urethral discharge.
The vast majority of men will have no abnormal signs on examination.
Diagnostic différentiel
Other vaginal infections - eg, candidose, BV, chlamydia, gonorrhée, herpes simplex.
Other benign causes of vaginal discharge - eg, physiological discharge, chemical irritants, foreign body, pregnancy, cervical ectropion.
Postmenopausal vaginal discharge due to vaginite atrophique.
Vaginal discharge after gynaecological surgery.
Autres causes de prostatite, urethritis, cervicitis and cystite.
Enquêtes2
Si Trichomonas vaginalis is suspected, a high vaginal swab can be taken from the posterior fornix but sensitivity may be low because motility reduces with transit time.
Self-administered vaginal swabs are increasingly being performed.
If symptoms are convincing but swabs taken in general practice are negative, referral to a genitourinary clinic is therefore recommended for confirmation by wet microscopy which should be read within 10 minutes of collection.
Laboratories may not routinely perform wet microscopy or Trichomonas vaginalis culture unless asked, so suspected Trichomonas vaginalis should be mentioned on the laboratory request form.
Femmes avec Trichomonas vaginalis need testing for other STIs.
Urethral culture or culture of first-void urine will diagnose 60-80% of cases in men.
Screening of asymptomatic people (including those who are pregnant) is currently not recommended.
Nucleic acid amplification tests (NAATs) offer the highest sensitivity for the detection of Trichomonas vaginalis. They should be the test of choice where resources allow and are becoming the current gold standard.
Trichomonas vaginalis treatment2
Both partners should ideally be treated at the same time.
Sexual intercourse should be avoided for at least one week following receiving treatment.
All patients should receive clear and accurate written information about this condition.
Although TV is easily treated with metronidazole in most cases, resistant strains are on the increase. 7
Systemic treatments are far more effective than topical treatments and include:
Oral metronidazole 2 g as a single dose (not during pregnancy or breastfeeding).
Oral metronidazole 400 mg to 500 mg bd for five to seven days.
Oral tinidazole 2 g single dose could theoretically be given as an alternative if metronidazole is not effective, but is not currently available in the UK.
Treatment of partners is recommended, regardless of their results.
Test of cure is only recommended if symptoms persist or recur.
Complications6
Complications of Trichomonas vaginalis inclure :
Pregnancy related:
Preterm delivery and low birth weight.
Trichomonas vaginalis infection at delivery may predispose to maternal postpartum sepsis.
Non-pregnancy related:
There is evidence that trichomoniasis infection enhances VIH acquisition.
Persistent and recurrent Trichomonas vaginalis infections are frequent in women, potentially due to the lack of routine screening recommendations for this pathogen, the chronic nature of some infections and also drug resistance.8
Prostatite can occur in men and studies also suggest a possible role for T. vaginalis in the development of clinically significant cancer de la prostate.910
Pronostic
Up to a third of cases may resolve spontaneously. 1112 Patients who are treated with metronidazole have a 90-95% cure rate but recurrent infections are common in sexually active individuals.6 The cure rates are even higher when the sexual partner is treated. Trichomoniasis is strongly associated with the presence of other STIs including HIV, gonorrhée, virus du papillome humain (HPV), herpès et chlamydia.
Mises à jour exclusives pour les professionnels de la santé
Restez informé des dernières mises à jour cliniques, des perspectives professionnelles et des conseils fondés sur des preuves. La newsletter Patient Pro sélectionne des contenus essentiels pour les professionnels de santé—livrés directement dans votre boîte de réception.
En vous abonnant, vous acceptez notre Politique de confidentialité. Vous pouvez vous désabonner à tout moment. Nous ne vendons jamais vos données.
Lectures complémentaires et références
- Land KM, Wrischnik LA; Basic biology of Trichomonas vaginalis: current explorations and future directions. Sex Transm Infect. 2013 Sep;89(6):416-7. doi: 10.1136/sextrans-2013-051153.
- Recommandations nationales du Royaume-Uni sur la prise en charge de Trichomonas vaginalis; British Association for Sexual Health and HIV - BASHH (2021)
- Trichomonase; World Health Organization, Nov 2025.
- Infections sexuellement transmissibles (IST); World Health Organization, Sept 2025
- Trichomonase; NICE CKS, mai 2020 (accès réservé au Royaume-Uni)
- Schumann JA, Plasner S; Trichomoniasis
- Alessio C, Nyirjesy P; Management of Resistant Trichomoniasis. Curr Infect Dis Rep. 2019 Aug 6;21(9):31. doi: 10.1007/s11908-019-0687-4.
- Sena AC, Bachmann LH, Hobbs MM; Persistent and recurrent Trichomonas vaginalis infections: epidemiology, treatment and management considerations. Expert Rev Anti Infect Ther. 2014 Jun;12(6):673-85. doi: 10.1586/14787210.2014.887440. Epub 2014 Feb 20.
- Tsang SH, Peisch SF, Rowan B, et al; Association between Trichomonas vaginalis and prostate cancer mortality. Int J Cancer. 2019 May 15;144(10):2377-2380. doi: 10.1002/ijc.31885. Epub 2018 Dec 4.
- Yang HY, Su RY, Chung CH, et al; Association between trichomoniasis and prostate and bladder diseases: a population-based case-control study. Sci Rep. 2022 Sep 13;12(1):15358. doi: 10.1038/s41598-022-19561-2.
- Van Gerwen OT, Muzny CA; Recent advances in the epidemiology, diagnosis, and management of Trichomonas vaginalis infection. F1000Res. 2019 Sep 20;8. doi: 10.12688/f1000research.19972.1. eCollection 2019.
- Trichomonase; DermNet, Sept 2019
À propos du critiqueVoir la biographie complète

Dr Hayley Willacy, FRCGP
Médecin généraliste, Auteur médical
MBChB (1992), DRCOG, DFFP, MRCOG (Part 1) MRCGP (2007), DFSRH (2013), MSc - medical education (2020)
Le Dr Hayley Willacy était médecin généraliste au NHS travaillant dans le nord-ouest de l'Angleterre, qui a pris sa retraite de la pratique clinique en 2022 après 30 ans.
Historique de l'article
Article également disponible en Anglais, Allemand, Espagnol, Français, Italien, Portugais, Hindi, Hébreu, Arabe, and Suédois.
Prochaine révision prévue : 30 sept. 2030
30 mars 2026 | Dernière version
Plus en gynécologie
- Infections anténatales et leurs conséquences
- Présentations par le siège
- Antigène du cancer 125
- Hyperplasie de l'endomètre
- Prélèvement endométrial
- Endométriose
- Anomalies génitales féminines
- Examen gynécologique et antécédents
- THS - évaluations de suivi
- Traitements de l'infertilité
- Ménopause et sa gestion
- Douleur pelvienne
- Saignement postménopausique
- Fièvre puerpérale
- Thérapie sexuelle et conseil
- Infections sexuellement transmissibles
- Rupture utérine
- Candidose vaginale et vulvaire
- Cancer vaginal
- Cancer de la vulve et néoplasie intraépithéliale vulvaire


